PerkinElmer to Expand Cell and Gene Therapy and Biologics Manufacturing with $260 Million Nexcelom Acquisition

PerkinElmer said it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.

Photo: Prahlad Singh, president and CEO of PerkinElmer

The transaction, which is expected to close during the second quarter of 2021, will help PerkinElmer expand its cell and gene therapy and biologics manufacturing.

Nexcelom is a global provider of automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines.

Headquartered in Lawrence, Massachusetts, Nexcelom is founder-led, privately held and has approximately 130 employees around the world based in the United States, the United Kingdom, and China. Nexcelom’s expected 2021 revenues are approximately $40 Million.

“This combination will expand our efforts to help academic, government and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies,” said Prahlad Singh, president and CEO of PerkinElmer.

The agreement to acquire Nexcelom comes just five months after PerkinElmer acquired Horizon Discovery, a leader in gene editing and modulation.

Author: Rare Daily Staff